Master Protocols & IRT: 5 Questions Sponsors Must Ask Before Selecting a Randomisation Partner

Date:

Master Protocols-including platform, umbrella, and basket trials-offer significant benefits and efficiencies in drug development compared with traditional trial protocols. However, their perpetual nature, adaptive designs, and evolving requirements make randomisation inherently more complex. As a result, implementing and maintaining robust randomisation for Master Protocols can be challenging for sponsors. Selecting the right IRT provider is therefore critical. This paper outlines five essential questions sponsors should ask when evaluating IRT providers for Master Protocols, with a focus on long-term trial success, regulatory readiness, and operational resilience.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

Popular

More like this
Related

Innovation Insight: Secure Enterprise Browsers

Gartner defines a secure enterprise browser as a solution...

Public Sector Ignite 2025 | Securing AI by Design: Building Trustworthy AI at Scale

Stop chasing threats and start building a resilient defense...

Secure AI by Design

Artificial Intelligence is rapidly transforming government and enterprise operations,...

Automate 75% of manual tasks in the SOC.

U.S. federal and DoD SOCs are challenged by rapidly...